Related Experiment Videos
Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
M Schmidinger1, C Wenzel, G J Locker
1Department of Internal Medicine I, Division of Clinical Oncology, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
British Journal of Cancer
|December 19, 2001
Abstract:
We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxicities were moderate. In view of these encouraging findings, further studies appear warranted.